NCT06595797尚未招募2 期
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 144
- 主要终点
- Percentage change in body weight from baseline at 32 weeks of treatment
研究概览
简要总结
Randomized, double-blind, placebo-controlled study of HRS9531 in PCOS subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •With my consent and signed informed consent, I am willing and able to complete this study in accordance with the requirements of the experimental protocol
- •Women aged 18-40 (including the threshold) on the date of signing the informed consent;
- •Patients who meet the diagnostic criteria for polycystic ovary syndrome;
- •Body mass index (BMI) ≥28 kg/m2;
- •Have controlled diet and exercise for at least 3 months, and the weight change is less than 5 kg
- •Within 2 months from the signing of the informed consent to the last drug use, there is no family planning and consent to take trial-approved contraceptive measures, and there is no egg donation plan
排除标准
- •Endometrial biopsy is necessary as assessed by the investigators, and the pathology of the endometrial biopsy indicates significant abnormalities
- •12-lead electrocardiogram (ECG) results showing clinically significant abnormalities that may affect the safety of the subject, including but not limited to myocardial infarction, severe arrhythmias (e.g., supraventricular tachycardia, atrial fibrillation, atrial flutter, degree II or III atrioventricular block, etc.), and QTcF > 470 ms
- •Poor blood pressure control (with or without antihypertensive therapy) : systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg at screening
- •PHQ-9 score ≥15 points
- •The presence of endocrine disorders or medical history that may significantly affect body weight
- •Presence of other medical conditions or history that may cause hyperandrostenia or irregular menstruation
- •Presence of a history of gynecological conditions that may affect the evaluation of menstruation (including, but not limited to, history of hysterectomy, vaginal atresia, uterine adhesions)
- •Abnormal uterine bleeding for reasons other than PCOS or unexplained abnormal uterine bleeding occurred within 6 months
- •Endometrium-related surgery within 1 year indicated significant pathological abnormalities of endometrial tissue, and safety risks were assessed by researchers
- •History of pregnancy, miscarriage, childbirth or breastfeeding within 6 months
- •Have any disease or history that affects gastric empty. such as gastric bypass surgery, pyloric stenosis, etc., long-term use of drugs that directly affect gastrointestinal motility, serious gastrointestinal disease (such as active peptic ulcer, inflammatory bowel disease, etc.), or have undergone gastrointestinal surgery (except surgery that has no significant effect on gastrointestinal motility), Such as gastrointestinal polypectomy, appendectomy and hemorrhoid surgery);
- •A history or disease of acute or chronic pancreatitis or pancreatic injury; Patients with a history of acute cholecystitis or symptomatic/treatable gallbladder disease (except those who had previously undergone cholecystectomy and were deemed eligible by the investigator to be enrolled);
- •History or family history of medullary thyroid carcinoma (MTC) or multiple endocrine adenomatosis type 2 (MEN2);
- •Severe infection, severe trauma, or major or major surgery in the previous 6 months
- •A history of severe cardiovascular and cerebrovascular disease, including decompensated heart failure (New York Heart Association ratings III and IV), unstable angina pectoris, stroke or transient ischemic attack, myocardial infarction, severe arrhythmia, or coronary bypass grafting or percutaneous coronary intervention within the previous 6 months;
- •Any organ-system malignancy within the previous 5 years, regardless of evidence of local recurrence or metastasis, except cured local basal cell carcinoma of the skin, cervical carcinoma in situ, and prostate carcinoma in situ;
- •Present or suspected depression, anxiety disorder, bipolar disorder, suicidal tendencies, schizophrenia, or other more serious mental illness
- •A known or suspected history of alcohol and/or drug abuse or drug use
- •A history of acute or chronic hepatitis, or other serious liver disease other than alcoholic fatty liver disease;
- •A history of unstable or rapidly progressing kidney disease or end-stage kidney disease
- •Autoimmune disease is present and systemic glucocorticoid therapy or immunosuppressive therapy is planned for the study period;
- •Participated in a clinical trial of any drug or medical device within the previous 3 months, defined as signing informed consent and using the investigational drug (including placebo) or the investigational medical device; Or is still in the trial drug within 5 half-lives (whichever is older);
- •Those who have donated blood or lost blood ≥400 mL in the previous 3 months, or received blood transfusion
- •Surgery is planned during the trial period (except for minor surgery that the investigator believes will not affect the trial);
- •Mentally incapacitated or speech-impaired subjects are unable to fully understand or participate in the test process;
- •Researchers and relevant staff of the research Centre or others directly involved in the implementation of the programme, as well as members of their immediate family (e.g. spouse, legal partner, parents, children or siblings); Hengrui company staff;
- •There are circumstances (medical, psychological, social or geographical factors, etc.) that, in the investigator's judgment, affect the subject's safety or any other conditions that interfere with the evaluation of the test results.
研究组 & 干预措施
Treatment group 2
Experimental
干预措施: HRS9531placebo (Drug)
Treatment group 3
Experimental
干预措施: HRS9531 (Drug)
Treatment group 3
Experimental
干预措施: HRS9531placebo (Drug)
Treatment group 1
Experimental
干预措施: HRS9531 (Drug)
Treatment group 1
Experimental
干预措施: HRS9531placebo (Drug)
Treatment group 2
Experimental
干预措施: HRS9531 (Drug)
结局指标
主要结局
Percentage change in body weight from baseline at 32 weeks of treatment
时间窗: 0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week
次要结局
- Proportion of subjects with regular menstruation at 32 weeks of treatment(0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week)
- Change in spontaneous menstrual frequency ratio from baseline at 32 weeks of treatment(0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week)
- Proportion of subjects who ovulated regularly after 32 weeks of treatment(0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week)
- Proportion of subjects with weight loss of ≥5%, ≥10%, ≥15%, ≥20% from baseline at 32 weeks of treatment(0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week)
- BMI changes relative to baseline after 32 weeks of administration;(0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week)
- Changes in waist circumference (WC) from baseline after 32 weeks of administration(0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week)
- Proportion of subjects with at least 3 menstrual cycles of 21-35 days after 12-32 weeks of treatment;(0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week)
- Changes in total testosterone (TT)from baseline after 32 weeks of administration(0week, 12week, 24week, 32week)
- Changes in sex hormone binding globulin (SHBG)from baseline after 32 weeks of administration(0week, 12week, 24week, 32week)
- Changes in free testosterone index (FAI),from baseline after 32 weeks of administration(0week, 12week, 24week, 32week)
- Changes in anti-Miller tube hormone (AMH),from baseline after 32 weeks of administration(0week, 12week, 24week, 32week)
- Changes in follicle stimulating hormone (FSH),from baseline after 32 weeks of administration(0week, 12week, 24week, 32week)
- Changes in luteinizing hormone (LH)from baseline after 32 weeks of administration(0week, 12week, 24week, 32week)
- Changes in LH/FSH;from baseline after 32 weeks of administration(0week, 12week, 24week, 32week)
- Changes in fasting plasma glucose (FPG)from baseline after 32 weeks of administration(0week, 12week, 24week, 32week)
- Changes in fasting serum insulin (FINS),from baseline after 32 weeks of administration(0week, 12week, 24week, 32week)
- Changes in insulin resistance index (HOMA-IR)from baseline after 32 weeks of administration(0week, 12week, 24week, 32week)
- Changes in triglycerides from baseline after 32 weeks of administration(0week, 12week, 24week, 32week)
- Changes in total cholesterol (TC),from baseline after 32 weeks of administration(0week, 12week, 24week, 32week)
- Changes in, low density lipoprotein cholesterol (LDL-C)from baseline after 32 weeks of administration(0week, 12week, 24week, 32week)
- Changes in high density lipoprotein cholesterol (HDL-C)from baseline after 32 weeks of administration(0week, 12week, 24week, 32week)
- Changes in blood pressure from baseline(0week, 4week,12week, 24week, 32week)
- Adverse events,(0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week)
研究者
相似试验
已完成
2 期
Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes SubjectsType 2 DiabetesNCT05966272Fujian Shengdi Pharmaceutical Co., Ltd.199
已完成
2 期
Efficacy and Safety of HRS9531 Injection in Obese Subjects Without DiabetesOverweight or ObesityNCT05881837Fujian Shengdi Pharmaceutical Co., Ltd.249
已完成
3 期
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 DiabetesType 2 DiabetesNCT06649344Fujian Shengdi Pharmaceutical Co., Ltd.884
已完成
3 期
the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise AloneDiabetes Mellitus, Type 2NCT06650007Fujian Shengdi Pharmaceutical Co., Ltd.218
尚未招募
2 期
A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep ApneaWeight ManagementNCT06565871Fujian Shengdi Pharmaceutical Co., Ltd.108